Clinicopathological and prognostic value of hypoxia-inducible factor-1α in patients with bone tumor: a systematic review and meta-analysis

Table 3 The subgroups analysis for HIF-1α and OS in patients with bone tumor

Subgroups	Number of studies	Case (n)	HIF-1α + (n)	HIF-1α + (%)	Pooled data			Test for heterogeneity
Subgroups	Number of studies	Case (n)	HIF-1α + (n)	HIF-1α + (%)	HR	95% CI	P value	P value	I² (%)
Histological type
Osteosarcoma	9	622	364	59	2.60	2.09–3.24	< 0.001	0.684	0
Chondrosarcoma	1	34	20	59	2.83	1.11–7.22	0.030	NA	NA
Case (n)
< 50	5	200	114	57	2.40	1.84–3.12	< 0.001	0.770	0
≥ 50	5	456	270	59	3.07	2.14–4.40	< 0.001	0.451	0
Follow-up (months)
< 100	5	294	184	50	2.55	1.97–3.30	< 0.001	0.578	0
≥ 100	5	362	236	65	2.76	1.88–4.04	< 0.001	0.608	0
Quality
High	7	416	224	54	2.70	2.13–3.43	< 0.001	0.581	0
Low	3	240	160	67	2.30	1.44–3.68	< 0.001	0.732	0

OS overall survival, HIF-1α + hypoxia-inducible factor-1α expression, HR hazard ratio, CI confidence interval, NA not available due to single study

ISSN: 1749-799X